Completed PHASE4 INTERVENTIONAL NCT00372827

Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension

Efficacy and Safety of Timolol Maleate 0.5% Compared to Brinzolamide 1% When Added to Travoprost 0.004% in Primary Open-angle Glaucoma or Ocular Hypertension

Sponsor: Alcon Research

Conditions Ocular Hypertension Pigment Dispersion Glaucoma Primary Open-angle Glaucoma

Interventions Brinzolamide 1% added to Travoprost 0.004%

Updated 5 times since 2017 Last updated: Nov 18, 2016 Started: Feb 29, 2004 Primary completion: Jan 31, 2006 Completion: Jan 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00372827, this PHASE4 trial focuses on Ocular Hypertension and Pigment Dispersion Glaucoma and remains completed. Sponsored by Alcon Research, it has been updated 5 times since 2004, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alcon Research

Data source: Alcon Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mainz, Germany